The $55m cap raise in October 2020 was proposed to fund the VP-001 program through to market, IND-enabling studies for two more eye programs and development of the first CNS asset (see below).
The company has been so shockingly off-target in meeting those objectives with the funds raised, especially with the lead program which is yet to commence dosing, that I think an explanation is warranted.
The $55m cap raise in October 2020 was proposed to fund the...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
0.020(1.59%) |
Mkt cap ! $743.6M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.28 | $1.24 | $46.67K | 37.07K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15857 | $1.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |